以前沒注意到的俄罗斯疫苗的消息:
俄期待今秋开始大规模接种新冠疫苗-新华网
俄期待今秋开始大规模接种新冠疫苗 ---俄罗斯副总理德米特里·切尔内申科2日说,俄罗斯有望今年秋天开始大规模接种新冠疫苗。
www.xinhuanet.com
这个疫苗是中美合作的吗?
2 hr 23 min ago
Human trial begins in China on another potential Covid-19 antibody therapy
From CNN Health’s Jen Christensen
Doctors dosed a healthy volunteer on Monday with an antibody treatment developed by Eli Lilly and Chinese company Junshi Biosciences to fight Covid-19.
The trial is underway in China. Lilly will start a complementary Phase one study in the United States in the next few days, the company said.
Scientists will first test to see if this antibody treatment, called JS016, is safe to be used in humans. If so, it will be tested to see if it if effective.
If this first phase is successful, more trials will run to determine how to use it most effectively.
The companies will also experiment to see if the antibody could be used on its own or if it would be more effective used in combination with other antibody candidates. JS016 appeared to neutralize the virus in the lab. Lilly and Junshi scientists are testing other potential antibodies in the lab to see which work best.
This is the second such antibody therapy trial from the Indianapolis-based pharmaceutical company. Lilly is testing another antibody treatment called LY-COV555 that the company developed with AbCellera.
Junshi Biosciences is leading development in greater China, according to Lilly, and Eli Lilly has exclusive rights to it in the rest of the world.
There are several other companies trying to create antibody therapies to fight Covid-19, including Regeneron Pharmaceuticals, which has said it expects to begin clinical trials this month.
Some background: Antibodies are proteins your body makes in the thousands that naturally fight off infection. To make an antibody therapy, scientists have to sort through thousands of antibodies to determine which work best to neutralize a particular threat.
Typically, drug developers will pick one and then clone it until there are enough monoclonal antibodies to put in a medicine.
Antibody treatments are currently used to treat some cancers, eye problems, chronic and infectious disease. The treatments can be used to treat symptoms or potentially as a protective medicine to prevent infection in vulnerable populations like the elderly or in health care workers.
The company did not say how many people would be studied in the clinical trials or how long they would take."These animals are producing neutralizing antibodies that kill (the novel coronavirus) in the laboratory," Eddie Sullivan, CEO of SAB Biotherapeutics said in a statement to CNN. "We are eager to advance to the clinic as we move forward in the regulatory process with the hopes of bringing this potential COVID-19 therapeutic to patients in need of a solution."
那么多好说关心加拿大,关心中加友好关系的,怎么从来没见来关心一下这个处于世界领先地位的中加合作疫苗进展?关心都是怎么体现的?又一陈薇团队的消息:
2020-06-24 12:39:07
陈薇团队:新冠病毒抗体研究取得重大突破--万维读者网
据《解放军报》消息,中国科学家在新型冠状病毒抗体研究中取得重大突破。由中国工程院院士、军事科学院军事医学研究院研究员陈薇领衔的团队,发现了首个靶向刺突蛋白N端结构域的高效中和单克隆抗体。北京时间6月22日22:00,国际顶级学术期刊《科学》在线发表news.creaders.net
据《解放军报》消息,中国科学家在新型冠状病毒抗体研究中取得重大突破。由中国工程院院士、军事科学院军事医学研究院研究员陈薇领衔的团队,发现了首个靶向刺突蛋白N端结构域的高效中和单克隆抗体。北京时间6月22日22:00,国际顶级学术期刊《科学》在线发表了该项研究结果。这也是陈薇团队研发的腺病毒载体重组新冠疫苗在全球率先进入Ⅱ期临床试验后,取得的又一项世界级科研成果。
How the study was conducted: For the initial study, 45 participants ages 18 to 55 were randomly assigned to either receive a certain dose of the vaccine or placebo."These clinical findings for the BNT162b1 RNA-based vaccine candidate are encouraging and strongly support accelerated clinical development and at-risk manufacturing to maximize the opportunity for the rapid production of a SARS-CoV-2 vaccine to prevent COVID-19 disease," the researchers wrote in the pre-print paper, which was sponsored by BioNTech and designed by Pfizer.
3 hr 23 min ago
Scientist leading Oxford vaccine effort says 8,000 people in UK vaccinated in phase three of the trial
From CNN's Jo Shelley in London
Eight thousand people in the UK have been vaccinated so far as part of the Oxford University vaccine trial, Sarah Gilbert, professor of vaccinology at the University of Oxford, and one of the scientist leading its vaccine initiative, told UK’s Science and Technology Committee on Wednesday.
“We now have 8,000 people vaccinated in the phase three trial in the UK,” she said.
“We have currently vaccinated a few hundred people in Brazil but within weeks that should be up to 4,000. And in South Africa, we are aiming for 2,000 people. And those are both areas of high transmission at the moment,” Gilbert added.
Sir John Bell, Regius professor of medicine at the University of Oxford, who is also working on the development of Covid-19 vaccine, was asked whether the UK should prepare for a winter without a vaccine.
He told the committee: “This whole epidemic has relied too heavily on assumptions that have turned out not to be true, so my strong advice is, be prepared for the worst.”